Island Pharmaceuticals Ltd. announced that ISLA-101 capsules for use in the upcoming Phase 2a PEACH clinical trial in dengue fever have completed analytical testing, further demonstrating the viability of the material for use in the trial. Following investigation of batch capsule samples, it has been confirmed that the capsules have excellent content uniformity, which is a measure of the consistency of the level of active ingredient in each of the capsules. The samples will now continue to undergo required stability studies and the Company expects to receive these results in early December 2022, allowing filing of the Investigational New Drug (IND) application submission with the US FDA in December.

The PEACH trial is then expected to commence in January 2023.